Comparable pharmacokinetics of 85 mg RightSize nilotinib (XS003) and 150 mg Tasigna in healthy volunteers using a hybrid nanoparticle-based formulation platform for protein kinase inhibitors

Authors :: Michael Beckert
Per Andersson
Mikael von Euler
Source :: Journal of Clinical Oncology. 32:e13551-e13551
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: e13551^ Background: Most of the protein kinase inhibitors (PKIs) have very challenging solubility properties and many products are suffering from pH dependent absorption, food effect and high varia...

Subjects :: Cancer Research
FOOD EFFECT
business.industry
Nanoparticle
Absorption (skin)
Pharmacology
Oncology
Pharmacokinetics
Nilotinib
Healthy volunteers
medicine
Solubility
business
Protein kinase A
medicine.drug

Tools